Tool overview
FinalDose is listed under AI for Science AI tools.
What is FinalDose?
FinalDose is a biotechnology company developing programmable therapeutics that recognize target DNA sequences inside cells and trigger a kill mechanism when the selected disease signature is found. Its initial focus is cancer and other mutation-driven conditions that are difficult to address through traditional protein targets.
Best for
Biotechnology and oncology researchers exploring programmable DNA-targeted therapeutics
Who is it for?
Decision note
Reviewed the official company site and Y Combinator company and launch materials. The programmable DNA-sensing therapeutic concept, initial cancer focus, 2025 founding, London location, five-person team, active status, and founders@finaldose.ai were confirmed. This is a research-stage biotechnology platform rather than a public SaaS tool.
Key features
Programs a therapeutic around a selected DNA sequence
Scans cellular DNA for a matching disease signature
Triggers a structural kill switch after recognition
Targets mutation-driven and traditionally undruggable diseases
Begins with broad cancer applications
Combines molecular biology with computational design
Use cases
Develop therapeutics for DNA-defined cancers
Investigate previously undruggable genetic targets
Design sequence-specific disease interventions
Translate human-genetics evidence into drug programs
Explore programmable treatments beyond protein targets
Pros
- Targets disease signatures at the DNA level
- Uses a reprogrammable platform concept
- Addresses targets missed by protein-first approaches
- Combines experienced molecular and computational researchers
Limitations
FinalDose is an early-stage therapeutic research company, not a clinical treatment or self-service AI application. Its claims require laboratory, preclinical, regulatory, and clinical validation. Availability, safety, efficacy, timelines, intellectual property, and target coverage may change substantially during development.
Pricing details
Pricing note
No public software plan, therapeutic price, or commercial purchasing model is available. FinalDose is an early-stage biotechnology research company. Commercial access, partnerships, licensing, research collaborations, and future treatment pricing require direct discussion with the company.
Supported languages
- English
Please log in to join the discussion.